Service Provider Oversight Section
A Service Provider Oversight section explains how outsourced trial work remains governed after transfer: selection, agreements, access to relevant information, performance oversight, escalation, and subcontracting controls. It is distinct from investigator delegation at an individual trial site.
A Service Provider Oversight section explains how the sponsor selects and supervises external providers while retaining responsibility for important trial activities and reliable results.
Key details
Important caveats
Scope Boundary
Keep sponsor service-provider oversight distinct from investigator-site delegation and from a generic Sponsor Role disclosure. Contracting and regulatory expectations vary by activity, jurisdiction, and provider type.
Further guidance
Content
Describe provider suitability assessment, documented transferred activities, access to relevant procedures/performance information, risk-proportionate oversight, incident escalation, and oversight of important subcontracted work.
Purpose
Show how outsourced work remains within the trial’s governance and quality system rather than implying that responsibility moves completely to the vendor.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification
- E6(R3) Good Clinical Practice (GCP) — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current FDA final-guidance overview for ICH E6(R3), including quality by design, risk-based quality management, technology, proportionality, and clarified sponsor/investigator responsibilities